Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
About a quarter of people taking a higher dose of Ocaliva saw an improvement in liver fibrosis.
Three fatty liver disease candidates miss the mark for effectiveness or safety.
The 2019 Liver Meeting in Boston provided an array of important findings about the treatment and prevention of chronic liver diseases.
This finding may help explain why people with the disease struggle to lose weight.
Currently, there are no pharmacological treatments for liver fibrosis related to non-alcoholic steatohepatitis.
Donna Cryer advocates for many liver-related conditions as founder and CEO of the Global Liver Institute.
Experimental therapy led to weight loss and improved biomarkers of liver health.
The treatment improved ALT liver enzymes, fat accumulation in the liver, insulin resistance and blood lipid levels.
Nonetheless, half of people with NAFLD were able to reach a 5% weight loss goal using a very low energy diet.
The new, minimally invasive outpatient procedure targets a part of the small intestine that plays a key role in diabetes.
Well-tolerated insulin sensitizer may play a role in the treatment of fatty liver disease.
Drugs that have a favorable effect on biomarkers may still play a role in combination therapy, however.
The tool relies on 14 clinical variables, such as liver enzymes, body mass index, triglycerides, height and sex.
This could provide a safer, simpler alternative to the invasive surgical biopsies used to diagnosis liver disease.
And yet there are no guidelines for screening for the disease in non-obese adolescents.
The injectable hormone was approved to treat excess abdominal fat in those with antiretroviral-associated lipodystrophy.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.